Skip to main content
See details

Reimbursement summary for angioplasty of arteries of lower extremities

This post presents an extract from our reimbursement analysis for angioplasty of arteries lower extremities using plain and drug-coated balloons (DCBs) for peripheral artery disease in England, France and Germany. Plain balloon angioplasty is reimbursement via DRG solely and DCBs are reimbursement via combination of DRG and add-on reimbursement.
See details

Reminder: Closing deadline for applications for conditional reimbursement in the Netherlands

21 Jun 2017

The deadline for acceptance of applications for conditional reimbursement in 2019 by the Care Institute Netherlands (Zorginstituut Nederland) is 29th of June 2017.

Conditional reimbursement for the period of up to 4 years can be available for promising technologies, which did not meet criteria for “state of science and practice” in the assessments of Zorginstituut Nederland.

The pre-condition for submission is available assessment from the Zorginstituut Nederland, which did not find evidence sufficient to recommend technology for reimbursement within basic insurance package, but mentioned possibility of conditional reimbursement.

Application triggers complex 4-stage process of selection of candidate technologies. During period of reimbursement, clinical trial shall be conducted in the Netherlands to bridge evidence gaps.

In 2016, five technologies were selected for conditional reimbursement from 2018, including 3 medical technologies:

  • Minimally invasive operation using Apollo System for spontaneous intracranial bleeding
  • Extracorporeal shock wave therapy for treatment of nonunion fractures of long bones
  • Use of exoskeleton in patients with paraplegia

See full source of information in Dutch here.

Subscribe to our newsletter delivered every second week not to miss important reimbursement information.